{"id":4008,"date":"2026-09-05T17:33:46","date_gmt":"2026-09-05T14:33:46","guid":{"rendered":"https:\/\/wniss.com\/?p=4008"},"modified":"2026-09-05T17:34:46","modified_gmt":"2026-09-05T14:34:46","slug":"clinical-advances-in-new-antidepressant-2022-treatments","status":"publish","type":"post","link":"https:\/\/wniss.com\/en-gb\/clinical-advances-in-new-antidepressant-2022-treatments\/","title":{"rendered":"Clinical Advances in New Antidepressant 2022 Treatments"},"content":{"rendered":"\n<div class=\"markdown prose dark:prose-invert wrap-break-word w-full light markdown-new-styling\"><h2><span class=\"ez-toc-section\" id=\"Clinical_Advances_in_New_Antidepressant_2022_Treatments\"><\/span>Clinical Advances in New Antidepressant 2022 Treatments<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The year <strong>2022<\/strong> marked an important turning point in depression treatment. Rather than relying only on traditional serotonin-based antidepressants, researchers and regulators increasingly focused on medications that target <strong>glutamate<\/strong>, <strong>GABA<\/strong>, and other novel brain pathways. Several promising therapies demonstrated faster symptom relief, particularly for people with <strong>treatment-resistant depression (TRD)<\/strong>. <span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 116px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">PubMed<\/span><\/span><span class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\">+1<\/span><\/span><\/span><\/span><\/span><\/span><\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_85 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/wniss.com\/en-gb\/clinical-advances-in-new-antidepressant-2022-treatments\/#Clinical_Advances_in_New_Antidepressant_2022_Treatments\" >Clinical Advances in New Antidepressant 2022 Treatments<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/wniss.com\/en-gb\/clinical-advances-in-new-antidepressant-2022-treatments\/#Why_2022_Was_Different\" >Why 2022 Was Different<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/wniss.com\/en-gb\/clinical-advances-in-new-antidepressant-2022-treatments\/#Auvelity_A_Landmark_FDA_Approval\" >Auvelity: A Landmark FDA Approval<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/wniss.com\/en-gb\/clinical-advances-in-new-antidepressant-2022-treatments\/#Continued_Expansion_of_Esketamine\" >Continued Expansion of Esketamine<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/wniss.com\/en-gb\/clinical-advances-in-new-antidepressant-2022-treatments\/#Emerging_Mechanisms_Beyond_Serotonin\" >Emerging Mechanisms Beyond Serotonin<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/wniss.com\/en-gb\/clinical-advances-in-new-antidepressant-2022-treatments\/#Psychedelic_Research\" >Psychedelic Research<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/wniss.com\/en-gb\/clinical-advances-in-new-antidepressant-2022-treatments\/#Faster-Acting_Antidepressants\" >Faster-Acting Antidepressants<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/wniss.com\/en-gb\/clinical-advances-in-new-antidepressant-2022-treatments\/#What_These_Advances_Mean_for_Patients\" >What These Advances Mean for Patients<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/wniss.com\/en-gb\/clinical-advances-in-new-antidepressant-2022-treatments\/#Key_Takeaways\" >Key Takeaways<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n\n<div class=\"TyagGW_tableContainer\"><div tabindex=\"-1\" class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\"><table class=\"w-fit min-w-(--thread-content-width)\"><thead><tr><th class=\"last:pe-10\">Treatment\/Approach<\/th><th class=\"last:pe-10\">2022 Status<\/th><th class=\"last:pe-10\">Mechanism<\/th><th class=\"last:pe-10\">Key Clinical Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Auvelity (dextromethorphan + bupropion)<\/strong><\/td><td>FDA approved (2022)<\/td><td>NMDA receptor modulation + norepinephrine\/dopamine effects<\/td><td>First oral rapid-acting antidepressant using NMDA modulation<\/td><\/tr><tr><td><strong>Esketamine (Spravato)<\/strong><\/td><td>Expanded clinical use<\/td><td>NMDA receptor antagonist<\/td><td>Effective option for treatment-resistant depression under medical supervision<\/td><\/tr><tr><td><strong>GABA-A modulators<\/strong><\/td><td>Active clinical development<\/td><td>Enhances inhibitory neurotransmission<\/td><td>Potential rapid symptom improvement<\/td><\/tr><tr><td><strong>Psychedelic-assisted therapies<\/strong><\/td><td>Phase II\/III research<\/td><td>Serotonin 5-HT2A receptor activation<\/td><td>Promising but still investigational in most settings<\/td><\/tr><tr><td><strong>Novel glutamate modulators<\/strong><\/td><td>Ongoing trials<\/td><td>Restores synaptic plasticity<\/td><td>May improve patients who fail conventional antidepressants<\/td><\/tr><\/tbody><\/table><div class=\"relative h-0 self-end select-none\"><div class=\"absolute end-0 flex items-end\" style=\"height: 48.8906px;\"><span class=\"\"><button aria-label=\"\u0646\u0633\u062e \u0627\u0644\u062c\u062f\u0648\u0644\" class=\"hover:bg-token-bg-tertiary text-token-text-secondary relative z-10 my-1 rounded-sm p-1 transition-opacity group-[:not(:hover):not(:focus-within)]:pointer-events-none group-[:not(:hover):not(:focus-within)]:opacity-0\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"20\" height=\"20\" aria-hidden=\"true\" class=\"icon\"><use href=\"\/cdn\/assets\/sprites-core-18ad762e.svg#ce3544\" fill=\"currentColor\"><\/use><\/svg><\/button><\/span><\/div><\/div><\/div><\/div>\n<h3><span class=\"ez-toc-section\" id=\"Why_2022_Was_Different\"><\/span>Why 2022 Was Different<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>For decades, most antidepressants belonged to familiar classes such as:<\/p>\n<ul>\n<li>\n<p>Selective serotonin reuptake inhibitors (SSRIs)<\/p>\n<\/li>\n<li>\n<p>Serotonin-norepinephrine reuptake inhibitors (SNRIs)<\/p>\n<\/li>\n<li>\n<p>Tricyclic antidepressants (TCAs)<\/p>\n<\/li>\n<li>\n<p>Monoamine oxidase inhibitors (MAOIs)<\/p>\n<\/li>\n<\/ul>\n<p>Although these medications help many people, they often require <strong>4\u20138 weeks<\/strong> before significant improvement occurs, and approximately one-third of patients experience inadequate response. This treatment gap accelerated research into therapies with entirely different mechanisms. <span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 78px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">bmj.com<\/span><\/span><span class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\">+1<\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"Auvelity_A_Landmark_FDA_Approval\"><\/span>Auvelity: A Landmark FDA Approval<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>One of the most significant advances in <strong>2022<\/strong> was the FDA approval of <strong>Auvelity<\/strong>, which combines:<\/p>\n<ul>\n<li>\n<p>Dextromethorphan<\/p>\n<\/li>\n<li>\n<p>Bupropion<\/p>\n<\/li>\n<\/ul>\n<p>Unlike conventional antidepressants, Auvelity influences the <strong>NMDA glutamate receptor<\/strong>, a pathway associated with brain plasticity and rapid mood improvement.<\/p>\n<p>Clinical trials showed:<\/p>\n<ul>\n<li>\n<p>Faster symptom reduction than many traditional antidepressants<\/p>\n<\/li>\n<li>\n<p>Improvement beginning within approximately one week for some patients<\/p>\n<\/li>\n<li>\n<p>Effectiveness in adults with major depressive disorder (MDD)<\/p>\n<\/li>\n<\/ul>\n<p>It became the <strong>first oral NMDA-modulating antidepressant<\/strong> approved in the United States. <span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 85px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">\u0628\u064a. \u0625\u0645. \u0633\u064a.<\/span><\/span><span class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\">+1<\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"Continued_Expansion_of_Esketamine\"><\/span>Continued Expansion of Esketamine<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Although <strong>Spravato (esketamine)<\/strong> received FDA approval before 2022, research during 2022 continued demonstrating its benefit for:<\/p>\n<ul>\n<li>\n<p>Treatment-resistant depression<\/p>\n<\/li>\n<li>\n<p>Patients with severe depressive symptoms<\/p>\n<\/li>\n<li>\n<p>Individuals requiring rapid symptom improvement<\/p>\n<\/li>\n<\/ul>\n<p>Esketamine differs from SSRIs because it targets the <strong>glutamate system<\/strong>, promoting synaptic remodeling instead of only increasing serotonin availability. Administration occurs in certified healthcare settings because monitoring is required after each dose. <span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 78px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">bmj.com<\/span><\/span><span class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\">+1<\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"Emerging_Mechanisms_Beyond_Serotonin\"><\/span>Emerging Mechanisms Beyond Serotonin<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Researchers increasingly recognized that depression involves multiple biological systems rather than serotonin deficiency alone.<\/p>\n<p>Major research areas included:<\/p>\n<ul>\n<li>\n<p>Glutamate signaling<\/p>\n<\/li>\n<li>\n<p>GABA neurotransmission<\/p>\n<\/li>\n<li>\n<p>Neuroplasticity<\/p>\n<\/li>\n<li>\n<p>Brain-derived neurotrophic factor (BDNF)<\/p>\n<\/li>\n<li>\n<p>Orexin pathways<\/p>\n<\/li>\n<li>\n<p>Opioid receptor modulation<\/p>\n<\/li>\n<\/ul>\n<p>These discoveries support a broader understanding of major depressive disorder and may lead to more personalized treatments. <span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 77px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">PubMed<\/span><\/span><span class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\">+1<\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"Psychedelic_Research\"><\/span>Psychedelic Research<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Clinical trials involving compounds such as <strong>psilocybin<\/strong> gained considerable attention in 2022.<\/p>\n<p>Early studies suggested:<\/p>\n<ul>\n<li>\n<p>Rapid antidepressant effects<\/p>\n<\/li>\n<li>\n<p>Potential benefit for treatment-resistant depression<\/p>\n<\/li>\n<li>\n<p>Long-lasting improvements after supervised therapy<\/p>\n<\/li>\n<\/ul>\n<p>However, these treatments remained investigational in most countries and were not considered standard first-line therapy. <span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 78px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">bmj.com<\/span><\/span><span class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\">+1<\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"Faster-Acting_Antidepressants\"><\/span>Faster-Acting Antidepressants<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>A major goal of 2022 research was reducing the delay before symptom relief.<\/p>\n<p>Scientists investigated:<\/p>\n<ul>\n<li>\n<p>Novel NMDA modulators<\/p>\n<\/li>\n<li>\n<p>Fast-acting glutamate-targeting compounds<\/p>\n<\/li>\n<li>\n<p>Molecules designed to increase synaptic plasticity within hours rather than weeks<\/p>\n<\/li>\n<\/ul>\n<p>Experimental work suggested that manipulating interactions involving the serotonin transporter and neuronal nitric oxide synthase (nNOS) could eventually produce rapid antidepressant effects, although these findings remained preclinical. <span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 73px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between overflow-hidden\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">Nature<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_These_Advances_Mean_for_Patients\"><\/span>What These Advances Mean for Patients<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The innovations of 2022 demonstrated that future antidepressant therapy may become:<\/p>\n<ul>\n<li>\n<p>Faster acting<\/p>\n<\/li>\n<li>\n<p>More individualized<\/p>\n<\/li>\n<li>\n<p>Less dependent on serotonin alone<\/p>\n<\/li>\n<li>\n<p>Better suited for treatment-resistant depression<\/p>\n<\/li>\n<li>\n<p>Focused on restoring healthy brain connectivity and neuroplasticity<\/p>\n<\/li>\n<\/ul>\n<p>Researchers continue evaluating long-term safety, comparative effectiveness, and optimal patient selection for these newer treatments. <span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 78px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">bmj.com<\/span><\/span><span class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\">+1<\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"Key_Takeaways\"><\/span>Key Takeaways<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<ul>\n<li>\n<p><strong>2022<\/strong> represented one of the most important years in modern antidepressant development.<\/p>\n<\/li>\n<li>\n<p><strong>Auvelity<\/strong> became the first approved oral NMDA-modulating antidepressant.<\/p>\n<\/li>\n<li>\n<p><strong>Esketamine<\/strong> continued expanding evidence for treatment-resistant depression.<\/p>\n<\/li>\n<li>\n<p>Research increasingly shifted toward <strong>glutamate<\/strong>, <strong>GABA<\/strong>, and <strong>neuroplasticity<\/strong> rather than serotonin alone.<\/p>\n<\/li>\n<li>\n<p>Psychedelic-assisted therapies showed encouraging clinical trial results but remained investigational in most healthcare systems. <span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 77px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">PubMed<\/span><\/span><span class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\">+2<\/span><\/span><span class=\"flex h-4 w-full items-center justify-between absolute\" style=\"opacity: 0; transform: translateX(10%);\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">bmj.com<\/span><\/span><span class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\">+2<\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<\/li>\n<\/ul><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Clinical Advances in New Antidepressant 2022 Treatments The year 2022 marked an important turning point in depression treatment. Rather than relying only on traditional serotonin-based antidepressants, researchers and regulators increasingly focused on medications that target glutamate, GABA, and other novel brain pathways. Several promising therapies demonstrated faster symptom relief, particularly for people with treatment-resistant depression&#8230;<\/p>\n","protected":false},"author":11,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[730],"tags":[],"class_list":["post-4008","post","type-post","status-publish","format-standard","hentry","category-depression"],"acf":[],"_links":{"self":[{"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/posts\/4008","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/comments?post=4008"}],"version-history":[{"count":2,"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/posts\/4008\/revisions"}],"predecessor-version":[{"id":5765,"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/posts\/4008\/revisions\/5765"}],"wp:attachment":[{"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/media?parent=4008"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/categories?post=4008"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/tags?post=4008"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}